188宝金博页面版

当代医学 2022年3月第28卷第8期总第631期 Contemporary Medicine，Mar.2022，Vol.28 No.8 Issue No.631伐他。捎跋焖⊙┡ǘ，导致横纹肌溶解发生。发生此类不良反应的高风险患者为肾功异常老年患者，最初使用瑞舒伐他汀时给予的剂量不当。此类患者给予替格瑞洛会增加瑞舒伐他汀浓度至临界水平风险，导致横纹肌溶解发生。替格瑞洛单独使用可导致肾脏损伤。通过本研究分析，提醒临床医生重视两药相互作用，两药联合使用时需监测肾功能且瑞舒伐他汀从小剂量5 mg开始使用。参考文献[1] 朱建兵,张俊峰.冠心病抗栓药物新进展[J].国际心血管病杂志,2014,41(3):163-166.[2] Wallentin L, Becker RC, BudajA, et al. Ticagrelor versus clopido-grel in patients with acute coronary syndromes[J]. N Engl J Med,2009,36(11):1045-1057.[3] Majda Vrki? Kirhmajer,Viola Macoli? Šarini? , Livija Šimi?evi? ,et al. Rosuvastatin-Induced Rhabdomyolysis-Possible Role of Ti-cagrelorand Patients’Pharmacogenetic Profile[J]. Basic ClinicalPharmacology Toxicology, 2018,123(4):509-518.[4] Samuel G, Atanda AC, Onyemeh A, et al. A Unique Case of DrugInteraction between Ticagrelor and Statin Leading to Acute RenalFailure[J]. Cureus, 2017,9 (8):e1633.[5] Park IS, Lee SB, SongSH, et al. Ticagrelor-induced acute kidneyinjury can increase serum concentration of statin and lead to con-currence of rhabdomyolysis[J]. Anatolian journal of cardiology,2018,19(3):225-226.[6] Mrotzek SM, Rassaf T, Totzeck M. Ticagrelor Leads to Statin-In-duced Rhabdomyolysis: A Case Report[J]. The American journalof case reports, 2017,18(4):1238-1241.[7] Calderon-Ospina CA, Hernandez-Somerson M, Garcia AM, et al.A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhab-domyolysis Case Evokes the Polygenic Nature of Adverse DrugReactions[J]. Pharmacogenomics and personalized medicine,2020,13(3):59-70.[8] Kariyanna, PT, Haseeb S, Chowdhury YS, et al. Ticagrelor andStatin Interaction Induces Rhabdomyolysis and Acute Renal Fail-ure: Case reports and Scoping Review[J]. American journal ofmedical case reports, 2019,7(12):337-341.[9] New J, Le K, Wong K, et al.Acase of acute renal failure and rhab-domyolysis associated with the concomitant use of Ticagrelor, Ro-suvastatinandLosartan[J].JMS InternMed, 2017,2(6):1004.[10] Noranjo CA, Busto U, Sellers EM, et al. A method for estimatingthe probability of adverse drug reaction[J]. Clin Pharmacol Ther,1981,30(2):239-245.[11] Chatzizisis YS, Koskinas KC, Misirli G, et al.Ｒisk factors anddrug interactions predisposing to statin-induced myopathy: impli-cations for risk assessment, prevention and treatment[J]. DrugSaf, 2010,33(3):171-187.[12] Ronaldson KJ, O’Shea JM, Boyd IW. Risk factors for rhabdomy-olysis with simvastatin and atorvastatin[J]. Drug Saf, 2006, 29(11):1061-1067.[13] Varenhost C, Eriksson N, JohanssonA, et al.Effect of genetic vari-ations on ticagrelor plasma levels and clinical outcome[J]. Euro-pean HeartJournal, 2015,36(29):1901-1912.[14] LI L, MIZEL D, HUANG Y, et al. Tubuloglomerular feedbackand renal function in mice with targeted deletion of the type 1equilibrative nucleoside transporter[J]. Am J Physiol Renal Physi-ol, 2013,304(4):F382-389.[15] MODLINGER PS,WELCH WJ. Adenosine A1 receptor antago-nists and the kidney[J]. Curr Opin Nephrol Hypertens, 2003,12(5):497-502.[16] Wallentin L, Beeker RC. Ticagrelor versusclopidogrel in patientswith acute coronary syndromes[J]. N EnglJ Med, 2009,361(11):1045-1057.4种人工晶体度数计算公式预测短眼轴白内障患者术后屈光度的准确性分析杨智1，史庆成1 ，吴海娟 2 ，周衍文 1*（1.沈阳爱尔眼视光医院白内障科，辽宁 沈阳 110003；2.康平爱尔眼科医院综合眼病科，辽宁 沈阳 110500）摘要：目的 比较Barrett UniversalⅡ、SRK-T、Hoffer Q和SRK-Ⅱ4种公式在短眼轴白内障患者中的人工晶体（IOL）度数计算的准确性。方法 回顾性分析沈阳爱尔眼视光医院2018年6月至2019年8月收治的短眼轴眼（＜22 mm）的白内障超声乳化人工晶体植入术18例（18眼）的临床资料。计算并比较4种公式预测IOL度数的平均绝对屈光度误差（mean absolute refractive error，MAE）。结果 BarrettUniversalⅡ公式、Hoffer Q公式与另两种公式比较误差较。钜煊型臣蒲б庖澹‵=3.149，P=0.022）。Barrett UniversalⅡ、SRK-T、Hoffer Q和SRK-Ⅱ公式误差在±0.5D以内的比例分别为44.4%、33.3%、38.9%、27.8%。SRK-T 公式和SRK-Ⅱ公式误差影响因素为眼轴长度（AL），Hoffer Q误差影响* 通信作者：周衍文，E-mail：zhouyanwen@vip.163.comdoi:10.3969/j.issn.1009-4393.2022.08.029 -- 论著 --— — 89